Valiant Laboratories

Jan 15 (Reuters) - Valiant Laboratories Ltd VALO.NS:

• VALIANT LABORATORIES LTD - RECEIVES NOTICE FOR TOTAL TAX DEMAND OF APPROX. 125.3 MILLION RUPEES

Source text: ID:nBSE16PLbx

Further company coverage: VALO.NS

(([email protected];))

July 9 (Reuters) - Valiant Laboratories Ltd VALO.NS:

• APPROVES RIGHTS ISSUE UP TO 814.7 MILLION RUPEES

Source text: ID:nBSE8VTFNq

Further company coverage: VALO.NS

(([email protected];;))

Nov 6 (Reuters) - Valiant Laboratories Ltd VALO.NS:

• INDIA'S VALIANT LABORATORIES LTD SEPT-QUARTER CONSOL NET PROFIT 7.9 MILLION RUPEES VERSUS PROFIT 86.6 MILLION RUPEES

• VALIANT LABORATORIES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 595.5 MILLION RUPEES VERSUS 879.6 MILLION RUPEES

Source text for Eikon: ID:nBSEbqk1q4

Further company coverage: VALO.NS

(([email protected];))

BENGALURU, Oct 6 (Reuters) - Shares of Indian pharmaceutical company Valiant Laboratories VALO.NS rose 15.8% in their trading debut on Friday, valuing the company at 5.28 billion rupees ($63.5 million).

The initial public offering of the Mumbai-based maker of paracetamol tablets was oversubscribed 29.8 times, with retail investors bidding 16 times and high net-worth investors 73.6 times.

The offering had fresh issue of shares worth 1.62 billion rupees ($19.5 million) at the top end of the 133-140 rupees price range.

Valiant is involved in the business of manufacturing active pharmaceutical ingredients (API) for pain killer drug Paracetamol.

Valiant competes with larger rivals such as Granules GRAN.NS and Glenmark Life Sciences GLEM.NS in the API market.

Earlier this week, Indian commercial port operator JSW Infrastructure's JSWN.NS listing saw a bumper opening with shares surging more than 32%.

($1 = 83.2025 Indian rupees)

(Reporting by Sethuraman NR and Kashish Tandon in Bengaluru; Editing by Sohini Goswami)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))